Evidence map›Paper›PMID 36301096›Full record

Observational studyMicrobiology spectrum2022

Secondary Bacterial Infections in Mucormycosis-COVID-19 Cases: Experience during the Second COVID-19 Wave in India.

Neha Sharad, Smriti Srivastava, Parul Singh, Mamta Puraswani, Sharad Srivastav, Rajesh Malhotra, Anjan Trikha, Purva Mathur

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Neha SharadDepartment of Microbiology, AIIMS, New Delhi, India.ORCID 0000-0002-0025-1649
Smriti SrivastavaDepartment of Microbiology, AIIMS, New Delhi, India.ORCID 0000-0002-7252-8993
Parul SinghDepartment of Microbiology, AIIMS, New Delhi, India.
Mamta PuraswaniDepartment of Laboratory Medicine, JPNATC, AIIMS, New Delhi, India.
Sharad SrivastavDepartment of Laboratory Medicine, JPNATC, AIIMS, New Delhi, India.
Rajesh MalhotraDepartment of Orthopaedic, AIIMS, New Delhi, India.
Anjan TrikhaDepartment of Anaesthesia, AIIMS, New Delhi, India.
Purva MathurDepartment of Laboratory Medicine, JPNATC, AIIMS, New Delhi, India.ORCID 0000-0003-4429-3688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the second wave of COVID-19 in India, there was a new challenge in the form of mucormycosis. Coinfection with mucormycosis was perilous as both conditions required a prolonged hospital stay, thus serving as an ideal platform for secondary infections. Using a retrospective observational study, we studied secondary infections and their impact on the outcome in COVID-19 patients with mucormycosis. The outcome in these patients was evaluated and compared with COVID-19 patients with mucormycosis but without any secondary infection. SPSS V-20 was used for data analysis. Fifty-five patients tested positive for mucormycosis (55/140; 39.28). Twelve out of these 55 (21.8%) developed secondary infections during their hospital stay. Bloodstream infection was the most common (42.86%) secondary infection. The Gram-negative (GN) organisms were more common (11/16; 68.75%) compared with the Gram-positives (GP) (5/16; 31.25%). But the most common isolate was Enterococcus faecium (5/16; 31.25%). A high percentage of microorganisms isolated were multidrug-resistant (15/16; 93.75%). Two out of five (40%) isolates of Enterococcus faecium were vancomycin-resistant (VRE). High resistance to carbapenems was noted in the GN isolates (9/11; 81.81%). The comparison of length of stay in both subgroups was statistically significant (

Indexed as

CoinfectionCOVID-19Enterococcus faeciumGram-Positive Bacterial InfectionsMucormycosisHumansCOVID-19mucormycosissecondary infections

Identifiers

PMID36301096
PMCPMC9769615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.